<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The NS-Plus automated analyzer and fecal immunochemical testing (FIT) testing system (Alfresa Pharma) was evaluated for use in Newfoundland and Labrador's provincial <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) screening program </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: Various method performance characteristics were evaluated including the sample stability </plain></SENT>
<SENT sid="2" pm="."><plain>The sensitivity for detecting neoplastic lesions was evaluated in 249 patients scheduled for colonoscopy </plain></SENT>
<SENT sid="3" pm="."><plain>Each patient collected up to 2 samples for both guaiac based testing (Hemoccult SENSA; gFOBT) and FIT using the NS-plus system (cutoff=20 μg Hb/g feces or 100 μg Hb/L) over 2 days </plain></SENT>
<SENT sid="4" pm="."><plain>Data was analyzed comparing 1- and 2-day testing strategies </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The analyzer showed acceptable linearity, precision, and accuracy </plain></SENT>
<SENT sid="6" pm="."><plain>The collection device maintained acceptable sample stability for at least 7 days at: 37 °C, room temperature (~23 °C), 4-8 °C, and -20 °C </plain></SENT>
<SENT sid="7" pm="."><plain>The 2-day sampling strategy identified 30% (21 of 69) of <z:hpo ids='HP_0000001'>all</z:hpo> neoplastic lesions (low and high grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) including 2 of 4 high-grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> and 2 of 2 CRCs </plain></SENT>
<SENT sid="8" pm="."><plain>The single day strategy identified the same high-grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> but fewer low-grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> (23% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0002664'>neoplasia</z:hpo>) </plain></SENT>
<SENT sid="9" pm="."><plain>Reducing the screening cutoff to the estimated 95th percentile of FIT results in the healthy adult population (10 μg Hb/g feces), detected <z:hpo ids='HP_0000001'>all</z:hpo> high-grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> in the 2-day strategy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The NS Plus automated analyzer system detects clinically significant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and shows acceptable performance for use in a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening program with the potential for gains in sensitivity by modifying the number of days of screening or through lowering the cutoff </plain></SENT>
</text></document>